Home » Topics » Disease categories and therapies » Respiratory

Respiratory
RSS

Trials terminated for HyperGAM+ for Pseudomonas lung infections

June 28, 1996

FK-506 undergoes phase II trials

June 28, 1996

Adenosine A3 antagonists from Merck & Co.

June 28, 1996

Eisai's ER-27319: Potential in treating allergic diseases

June 28, 1996

GCC-AP0341: Green Cross' eosinophilia inhibitor

June 28, 1996

5-lipoxygenase and cyclooxygenase inhibitors from Abbott

June 28, 1996

Abbott discloses 5-lipoxygenase inhibitors

June 28, 1996

Leukotriene biosynthesis inhibitors from Merck Frosst

June 28, 1996

Proctor & Gamble acquires Dura products

June 28, 1996

Thymosin beta4 as cystic fibrosis treatment

June 21, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 2, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 31, 2026
Hematopoietic stem cell research points to leukemia’s early roots
BioWorld Science
Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...
Molecular signatures show subtypes in neurodegenerative diseases
BioWorld Science
Parkinson’s disease is a progressive neurodegenerative disorder best known for its motor symptoms. However, a proportion of patients also develop dementia as the...
More than two to tango: multispecifics at ESMO TAT
BioWorld Science
Multispecifics took center stage at this year’s ESMO TAT, emerging as one of the hottest trends in oncology research. Unlike traditional small-molecule drugs or...